Rznomics

Focus: Rznomics is a Korean biotechnology company focused on RNA therapy platforms for gene therapy applications. The company is publicly listed and operates from Yongin, Korea.

Gene Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Rznomics

AI assessmentNot Hiring

No open roles listed right now. Follow Rznomics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RZ-001

Glioblastoma

N/A

Clinical Trials (1)

NCT06676891Expanded Access Program for GBM Subjects

N/A

Help build intelligence for Rznomics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge RNA therapy platform technology in an emerging therapeutic modality with significant upside potential
Opportunity to work on oncology programs (HCC and glioblastoma) with unmet medical needs and limited competition in early stages
Position at a publicly traded company provides liquidity and potential equity upside tied to pipeline advancement

Watch Out For

No current active job openings (0 posted roles) signals limited hiring momentum or internal focus
Early-stage pipeline (Phase 1/2 only, no Phase 3 programs) means 7-10+ years likely before any commercial revenue impact
Limited public visibility on financials, R&D spend, cash position, and clinical trial activity creates uncertainty about execution capability and runway

Generated by Claude from Rznomics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RZ-001 Dose 1

Hepatocellular Carcinoma (HCC)

Phase 1/2

Clinical Trials (1)

NCT06695026A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

Phase 1/2

RZ-001 Dose 1

Hepatocellular Carcinoma

Phase 1/2

Clinical Trials (1)

NCT05595473A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma

Phase 1/2

RZ-001

Glioblastoma

Phase 1/2

Clinical Trials (1)

NCT06102525A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

4 pipeline

Marketed

Pipeline